content: <?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
    <headerData>
      <submissionType>144</submissionType>
      <filerInfo>
        <filer>
          <filerCredentials>
            <cik>0001845875</cik>
            <ccc>XXXXXXXX</ccc>
          </filerCredentials>
        </filer>
        <liveTestFlag>LIVE</liveTestFlag>
  
  
      </filerInfo>
    </headerData>
    <formData>
      <issuerInfo>
        <issuerCik>0001798749</issuerCik>
        <issuerName>Aerovate Therapeutics, Inc.</issuerName>
        <secFileNumber>001-40544</secFileNumber>
        <issuerAddress>
          <com:street1>930 WINTER STREET</com:street1>
          <com:street2>SUITE M-500</com:street2>
          <com:city>WALTHAM</com:city>
          <com:stateOrCountry>MA</com:stateOrCountry>
          <com:zipCode>02451</com:zipCode>
        </issuerAddress>
        <issuerContactPhone>617-443-2400</issuerContactPhone>
        <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Atlas Venture Associates XII, L.P.</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
        <relationshipsToIssuer>
          <relationshipToIssuer>Director</relationshipToIssuer>
        </relationshipsToIssuer>
      </issuerInfo>
      <securitiesInformation>
        <securitiesClassTitle>Common</securitiesClassTitle>
        <brokerOrMarketmakerDetails>
          <name>Merrill Lynch</name>
          <address>
            <com:street1>555 California Street</com:street1>
            <com:street2>Floor 18</com:street2>
            <com:city>San Francisco</com:city>
            <com:stateOrCountry>CA</com:stateOrCountry>
            <com:zipCode>94104</com:zipCode>
          </address>
        </brokerOrMarketmakerDetails>
        <noOfUnitsSold>11882</noOfUnitsSold>
        <aggregateMarketValue>314635.36</aggregateMarketValue>
        <noOfUnitsOutstanding>27862961</noOfUnitsOutstanding>
        <approxSaleDate>04/09/2024</approxSaleDate>
        <securitiesExchangeName>NASDAQ</securitiesExchangeName>
      </securitiesInformation>
      <securitiesToBeSold>
        <securitiesClassTitle>Common</securitiesClassTitle>
        <acquiredDate>06/04/2021</acquiredDate>
        <natureOfAcquisitionTransaction>Private Placement</natureOfAcquisitionTransaction>
        <nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
        <isGiftTransaction>N</isGiftTransaction>
        <amountOfSecuritiesAcquired>11882</amountOfSecuritiesAcquired>
        <paymentDate>06/04/2021</paymentDate>
        <natureOfPayment>Cash</natureOfPayment>
      </securitiesToBeSold>
      <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
      <noticeSignature>
        <noticeDate>04/09/2024</noticeDate>
        <signature>Ommer Chohan</signature>
      </noticeSignature>
    </formData>
  </edgarSubmission>
metadata_documents: [{"type": "144", "sequence": "1", "filename": "primary_doc.xml", "secsgml_size_bytes": 2809}]
text: 144
  0001845875
  XXXXXXXX
  LIVE
  0001798749
  Aerovate Therapeutics, Inc.
  001-40544
  930 WINTER STREET
  SUITE M-500
  WALTHAM
  MA
  02451
  617-443-2400
  Atlas Venture Associates XII, L.P.
  Director
  Common
  Merrill Lynch
  555 California Street
  Floor 18
  San Francisco
  CA
  94104
  11882
  314635.36
  27862961
  04/09/2024
  NASDAQ
  Common
  06/04/2021
  Private Placement
  Issuer
  N
  11882
  06/04/2021
  Cash
  Y
  04/09/2024
  Ommer Chohan